| Date | Time | Source | Headline | Symbol | Company |
| 05/31/2024 | 6:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/31/2024 | 6:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/31/2024 | 6:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/31/2024 | 6:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/31/2024 | 6:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/31/2024 | 6:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/31/2024 | 4:10PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/29/2024 | 5:23PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/29/2024 | 4:55PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/29/2024 | 4:54PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/29/2024 | 4:53PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/29/2024 | 4:53PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/29/2024 | 4:53PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/29/2024 | 4:53PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/29/2024 | 4:53PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/29/2024 | 4:53PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/29/2024 | 4:02PM | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/17/2024 | 4:05PM | Business Wire | Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/15/2024 | 9:05AM | Business Wire | Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/09/2024 | 4:58PM | Business Wire | Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/08/2024 | 4:10PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 05/08/2024 | 4:05PM | Business Wire | Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 04/29/2024 | 4:16PM | Business Wire | Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 04/24/2024 | 4:05PM | Business Wire | Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 04/22/2024 | 9:04AM | Business Wire | Acadia Pharmaceuticals annonce que la présentation de drogue nouvelle pour la trofinetide dans le traitement du syndrome de Rett a été acceptée pour dépôt et évaluation prioritaire par Santé Canada | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 04/22/2024 | 9:04AM | Business Wire | Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 04/19/2024 | 4:05PM | Business Wire | Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 04/17/2024 | 4:05PM | Business Wire | Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 04/02/2024 | 4:05PM | Business Wire | Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 04/01/2024 | 4:05PM | Business Wire | Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |